| Literature DB >> 27457110 |
Gwang Sil Kim1, Jae-Sun Uhm1, Tae-Hoon Kim1, Hancheol Lee1, Junbeom Park1, Jin-Kyu Park1, Boyoung Joung1, Hui-Nam Pak1, Moon-Hyoung Lee2.
Abstract
BACKGROUND: This study aimed to determine the risk of thromboembolic events in patients with junctional bradycardia(JB).Entities:
Keywords: Junctional bradycardia; Stroke; Thromboembolic events
Mesh:
Year: 2016 PMID: 27457110 PMCID: PMC4959053 DOI: 10.1186/s12883-016-0645-9
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Baseline characteristics
| JB group | Control group |
| JB with P group | JB without P group |
| |
|---|---|---|---|---|---|---|
| Age (years) | 68.5 ± 16.5 | 68.4 ± 15.7 | 0.593 | 67.3 ± 16.6 | 69.2 ± 16.5 | 0.273 |
| Men, | 35 (50.7) | 72 (52.2) | 0.883 | 10 (41.7) | 25 (55.6) | 0.318 |
| Smoking, | 26 (37.7) | 40 (29.0) | 0.210 | 8 (33.3) | 18 (40.0) | 0.614 |
| Hypertension, | 39 (56.5) | 76 (55.1) | 0.883 | 11 (45.8) | 28 (62.2) | 0.213 |
| Diabetes mellitus, | 30 (43.5) | 50 (36.2) | 0.364 | 8 (33.3) | 22 (48.9) | 0.308 |
| Heart failure, | 6 (8.7) | 11 (8.0) | >0.999 | 3 (12.5) | 3 (6.7) | 0.412 |
| Chronic kidney disease, | 20 (29.0) | 22 (15.9) | 0.043 | 5 (20.8) | 15 (33.3) | 0.404 |
| History of CAD, | 21 (30.4) | 44 (31.9) | 0.875 | 3 (12.5) | 18 (40.0) | 0.027 |
| History of stroke, | 1 (1.4) | 1 (0.7) | >0.999 | 0 (0.0) | 1 (2.2) | >0.999 |
| Ejection fraction (%) | 64.2 ± 11.3 | 63.3 ± 11.0 | 0.485 | 63.8 ± 13.4 | 64.4 ± 10.1 | 0.772 |
| LAVI (ml/m2) | 45.1 ± 30.3 | 28.0 ± 11.3 | 0.001 | 40.8 ± 10.4 | 47.1 ± 36.1 | 0.740 |
| Antiplatelet agents, | 33 (47.8) | 101 (73.2) | 0.883 | 9 (37.5) | 24 (53.3) | 0.312 |
| Statin, | 26 (37.7) | 52 (37.7) | >0.999 | 7 (29.2) | 19 (42.2) | 0.312 |
| Anticoagulants, | 8 (11.6) | 6 (4.3) | 0.091 | 2 (8.3) | 6 (13.3) | 0.704 |
| CHADS2 score | 1.48 ± 1.16 | 1.49 ± 1.19 | 0.991 | 1.17 ± 1.13 | 1.64 ± 1.15 | 0.103 |
| 0, | 16 (23.2) | 32 (23.2) | 8 (33.3) | 8 (17.8) | ||
| 1, | 22 (31.9) | 44 (31.9) | 8 (33.3) | 14 (31.1) | ||
| 2, | 16 (23.2) | 32 (23.2) | 5 (20.8) | 11 (24.4) | ||
| 3, | 12 (17.4) | 24 (17.4) | 2 (8.3) | 10 (22.2) | ||
| 4, | 3 (4.3) | 6 (4.3) | 1 (4.2) | 2 (4.4)) | ||
| Follow-up duration (month) | 27.2 ± 26.2 | 25.4 ± 21.5 | 0.948 | 39.3 ± 36.5 | 20.7 ± 15.6 | 0.008 |
CAD coronary artery disease, JB junctional bradycardia, LAVI left atrial volume index
*comparison between the JB group and control group
**comparison between the JB without P group and JB with P group
Thromboembolic events
| JB with P group | JB without P group | Control group |
|
| |
|---|---|---|---|---|---|
| Stroke (%) | 0 | 4 (8.9) | 3 (2.2) | – | |
| TIA (%) | 0 | 2 (4.4) | 0 | ||
| Stroke and TIA (%) | 0 | 6 (13.3) | 3 (2.2) | 0.007* | |
| Renal infarction, | 1 (4.2) | 0 | 0 | – | – |
| Ischemic colitis, | 0 | 0 | 1 (0.7) | – | – |
| Acute limb ischemia, | 0 | 1 (2.2) | 0 | – | – |
| Pulmonary embolism, | 0 | 1 (2.2) | 0 | – | – |
| Composite thromboembolic events, | 1 (4.2) | 8 (17.8) | 4 (2.9) | 0.011** | 0.059*** |
JB junctional bradycardiaTIA transient ischemic attack
*comparison between the JB without P group and control group
**comparison among the JB without P group, JB with P group, and control group
***comparison between the JB without P group and JB with P group
Clinical information in patients with thromboembolic events
| Patients number | Age | Sex | Group | Heart rate | Thromboembolic events | Underlying disease |
|---|---|---|---|---|---|---|
| 1 | 74 | Female | Control | 70 | Stroke | HTN, CAD |
| 2 | 74 | Female | Control | 66 | Stroke | HTN, DM |
| 3 | 80 | Male | Control | 80 | Ischemic colitis | HTN, DM |
| 4 | 79 | Male | Control | 56 | Stroke | HTN, DM, CAD |
| 5 | 65 | Female | JB with P | 40 | Renal infarction | HTN |
| 6 | 66 | Female | JB without P | 40 | TIA | none |
| 7 | 73 | Male | JB without P | 46 | PAD | HTN, CAD (s/p CABG) |
| 8 | 80 | Male | JB without P | 50 | Pulmonary embolism | HTN, DM, CKD, CAD (s/p CABG) |
| 9 | 70 | Male | JB without P | 48 | Stroke | HTN, DM, s/p MVR |
| 10 | 86 | Male | JB without P | 50 | TIA | HTN |
| 11 | 80 | Male | JB without P | 52 | Stroke | HTN, DM, CKD (s/p kidney transplantation), CAD |
| 12 | 78 | Female | JB without P | 56 | Stroke | HTN, DM, CAD |
| 13 | 88 | Female | JB without P | 46 | Stroke | HTN, DM, CKD, CAD |
CABG coronary artery bypass graft surgery, CAD coronary artery disease, CKD chronic kidney disease, DM diabetes mellitus, HTN hypertension, JB junctional bradycardia, LAD left anterior descending, MVR mitral valve repair, P P wave, PAD peripheral artery disease, SCD sudden cardiac death, TIA transient ischemic attack
Independent predictors of thromboembolic events
| Univariable | Mutivariable | |||
|---|---|---|---|---|
| HR (95 % CI) |
| HR (95 % CI) |
| |
| a. Stroke and transient ischemic attack | ||||
| Male | 0.58 (0.14–2.34) | 0.472 | ||
| Chronic kidney disease | 1.95 (0.48–7.82) | 0.352 | ||
| CHADS2 score ≥2 | 5.74 (1.17–28.25) | 0.032 | 4.67 (0.96–22.73) | 0.062*** |
| LAVI (ml/m2) | 1.01 (0.97–1.06) | 0.562 | ||
| JB* | 2.60 (0.59–11.53) | 0.210 | ||
| JB without P** | 6.56 (1.61–26.75) | 0.007 | 8.89 (2.20–33.01) | 0.002*** |
| b. Composite thromboembolic events | ||||
| Male | 0.99 (0.36–3.27) | 0.993 | ||
| Chronic kidney disease | 1.75 (0.54–5.70) | 0.352 | ||
| CHADS2 score ≥2 | 3.44 (1.04–11.33) | 0.043 | 4.07 (1.11–14.87) | 0.031*** |
| LAVI (ml/m2) | 1.01 (0.99–1.03) | 0.391 | ||
| JB without P** | 5.69 (1.84–17.63) | 0.003 | 5.04 (1.68–15.09) | 0.004*** |
JB junctional bradycardia, LAVI left atrial volume index, P P wave
*comparison with the control group
**comparison with the control group and JB with P group
***adjustment for male sex, CHADS2 score ≥2, and JB without P group
Fig. 1Kaplan-Meier curve of the incidence of stroke at 48 months follow-up after the detection of junctional bradycardia. JB = junctional bradycardia; P = P wave; TIA = transient ischemic attack